TipRanks
Xencor Inc (DE:XE9)
FRANKFURT:XE9
Germany Market
XE9
Xencor
RESEARCH TOOLSreports

Xencor (XE9) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

XE9 Analyst Ratings

Strong Buy
13Ratings
Strong Buy
11 Buy
2 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Xencor
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

XE9 Stock 12 Month Forecast

Average Price Target

€28.23
▲(28.32% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Xencor in the last 3 months. The average price target is €28.23 with a high forecast of €40.58 and a low forecast of €17.64. The average price target represents a 28.32% change from the last price of €22.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"€8","41":"€41","16.25":"€16.25","24.5":"€24.5","32.75":"€32.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40.5811931,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€40.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.2303952,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€28.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.643997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€17.64</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,16.25,24.5,32.75,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.6,23.060091776923077,24.520183553846156,25.98027533076923,27.44036710769231,28.900458884615386,30.36055066153846,31.82064243846154,33.28073421538461,34.74082599230769,36.20091776923077,37.66100954615385,39.12110132307692,{"y":40.5811931,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.6,22.110030400000003,22.6200608,23.130091200000003,23.6401216,24.150152000000002,24.6601824,25.1702128,25.6802432,26.1902736,26.700304,27.2103344,27.7203648,{"y":28.2303952,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.6,21.29569207692308,20.991384153846155,20.687076230769232,20.38276830769231,20.078460384615386,19.774152461538463,19.469844538461537,19.165536615384614,18.86122869230769,18.556920769230768,18.252612846153845,17.948304923076922,{"y":17.643997,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.3,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.6,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.3,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.1,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.85,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.1,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.5,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.6,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€40.58Average Price Target€28.23Lowest Price Target€17.64
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on DE:XE9
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
€26.47
Buy
20.30%
Upside
Reiterated
09/29/26
Wells Fargo Reaffirms Their Buy Rating on Xencor (XNCR)
Truist Financial Analyst forecast on DE:XE9
Gregory Renza
Truist Financial
Truist Financial
€23.82→€25.58
Buy
16.29%
Upside
Reiterated
09/28/26
Analysts Offer Insights on Healthcare Companies: Xencor (NASDAQ: XNCR) and IQVIA Holdings (NYSE: IQV)
Wedbush Analyst forecast on DE:XE9
David Nierengarten
Wedbush
Wedbush
€26.47
Buy
20.30%
Upside
Reiterated
09/25/26
Analysts Are Bullish on Top Healthcare Stocks: Staar Surgical (STAA), Xencor (XNCR)
Bank of America Securities Analyst forecast on DE:XE9
Alec Stranahan
Bank of America Securities
Bank of America Securities
€22.94
Hold
4.26%
Upside
Reiterated
09/21/26
Xencor price target raised to $26 from $20 at BofAXencor price target raised to $26 from $20 at BofA
Barclays Analyst forecast on DE:XE9
Etzer Darout
Barclays
Barclays
€23.82→€30.88
Buy
40.35%
Upside
Reiterated
09/11/26
Xencor (XNCR) Receives a Buy from Barclays
J.P. Morgan Analyst forecast on DE:XE9
Brian Cheng
J.P. Morgan
J.P. Morgan
€12.35→€18.53
Hold
-15.79%
Downside
Reiterated
09/03/26
Xencor price target raised to $21 from $14 at JPMorganXencor price target raised to $21 from $14 at JPMorgan
Raymond James Analyst forecast on DE:XE9
Sean McCutcheon
Raymond James
Raymond James
€40.58
Buy
84.46%
Upside
Assigned
09/01/26
Xencor price target raised to $46 from $40 at Raymond JamesXencor price target raised to $46 from $40 at Raymond James
Cantor Fitzgerald Analyst forecast on DE:XE9
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
€38.82
Buy
76.44%
Upside
Reiterated
08/10/26
Analysts' Top Healthcare Picks: Xencor (XNCR), Revolution Medicines (RVMD)
Piper Sandler Analyst forecast on DE:XE9
Edward Tenthoff
Piper Sandler
Piper Sandler
€29.11
Buy
32.33%
Upside
Reiterated
08/06/26
Piper Sandler Remains a Buy on Xencor (XNCR)
William Blair Analyst forecast on DE:XE9
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Xencor Earns Buy Rating as XmAb541 and XmAb808 Advance Toward Differentiated Solid-Tumor Franchise
RBC Capital Analyst forecast on DE:XE9
Leonid Timashev
RBC Capital
RBC Capital
€16.76→€17.64
Buy
-19.80%
Downside
Reiterated
08/05/26
RBC Capital Sticks to Their Buy Rating for Xencor (XNCR)
TD Cowen Analyst forecast on DE:XE9
Tara Bancroft
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/05/26
Xencor: Buy Rating Backed by XmAb819 Expansion and Immunology Pipeline Milestones Ahead of Key 2026–2027 Data Catalysts
Canaccord Genuity Analyst forecast on DE:XE9
John Newman
Canaccord Genuity
Canaccord Genuity
€33.52
Buy
52.38%
Upside
Reiterated
08/05/26
Analyst John Newman Reiterates Buy on Xencor, Citing Late-Stage XmAb Pipeline, Non-Dilutive Cash Inflows and Royalties, and Sets $38 Price Target
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on DE:XE9
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
€26.47
Buy
20.30%
Upside
Reiterated
09/29/26
Wells Fargo Reaffirms Their Buy Rating on Xencor (XNCR)
Truist Financial Analyst forecast on DE:XE9
Gregory Renza
Truist Financial
Truist Financial
€23.82→€25.58
Buy
16.29%
Upside
Reiterated
09/28/26
Analysts Offer Insights on Healthcare Companies: Xencor (NASDAQ: XNCR) and IQVIA Holdings (NYSE: IQV)
Wedbush Analyst forecast on DE:XE9
David Nierengarten
Wedbush
Wedbush
€26.47
Buy
20.30%
Upside
Reiterated
09/25/26
Analysts Are Bullish on Top Healthcare Stocks: Staar Surgical (STAA), Xencor (XNCR)
Bank of America Securities Analyst forecast on DE:XE9
Alec Stranahan
Bank of America Securities
Bank of America Securities
€22.94
Hold
4.26%
Upside
Reiterated
09/21/26
Xencor price target raised to $26 from $20 at BofAXencor price target raised to $26 from $20 at BofA
Barclays Analyst forecast on DE:XE9
Etzer Darout
Barclays
Barclays
€23.82→€30.88
Buy
40.35%
Upside
Reiterated
09/11/26
Xencor (XNCR) Receives a Buy from Barclays
J.P. Morgan Analyst forecast on DE:XE9
Brian Cheng
J.P. Morgan
J.P. Morgan
€12.35→€18.53
Hold
-15.79%
Downside
Reiterated
09/03/26
Xencor price target raised to $21 from $14 at JPMorganXencor price target raised to $21 from $14 at JPMorgan
Raymond James Analyst forecast on DE:XE9
Sean McCutcheon
Raymond James
Raymond James
€40.58
Buy
84.46%
Upside
Assigned
09/01/26
Xencor price target raised to $46 from $40 at Raymond JamesXencor price target raised to $46 from $40 at Raymond James
Cantor Fitzgerald Analyst forecast on DE:XE9
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
€38.82
Buy
76.44%
Upside
Reiterated
08/10/26
Analysts' Top Healthcare Picks: Xencor (XNCR), Revolution Medicines (RVMD)
Piper Sandler Analyst forecast on DE:XE9
Edward Tenthoff
Piper Sandler
Piper Sandler
€29.11
Buy
32.33%
Upside
Reiterated
08/06/26
Piper Sandler Remains a Buy on Xencor (XNCR)
William Blair Analyst forecast on DE:XE9
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Xencor Earns Buy Rating as XmAb541 and XmAb808 Advance Toward Differentiated Solid-Tumor Franchise
RBC Capital Analyst forecast on DE:XE9
Leonid Timashev
RBC Capital
RBC Capital
€16.76→€17.64
Buy
-19.80%
Downside
Reiterated
08/05/26
RBC Capital Sticks to Their Buy Rating for Xencor (XNCR)
TD Cowen Analyst forecast on DE:XE9
Tara Bancroft
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/05/26
Xencor: Buy Rating Backed by XmAb819 Expansion and Immunology Pipeline Milestones Ahead of Key 2026–2027 Data Catalysts
Canaccord Genuity Analyst forecast on DE:XE9
John Newman
Canaccord Genuity
Canaccord Genuity
€33.52
Buy
52.38%
Upside
Reiterated
08/05/26
Analyst John Newman Reiterates Buy on Xencor, Citing Late-Stage XmAb Pipeline, Non-Dilutive Cash Inflows and Royalties, and Sets $38 Price Target
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ONCBeOne Medicines
OVIDOvid Therapeutics
WSTWest Pharmaceutical Services
ZYMEZymeworks
SLDBSolid Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Xencor

3 Months
David NierengartenWedbush
Success Rate
8/12 ratings generated profit
67%
Average Return
+17.88%
Copying David Nierengarten's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +17.88% per trade.
1 Year
John NewmanCanaccord Genuity
Success Rate
8/12 ratings generated profit
67%
Average Return
+31.42%
Copying John Newman's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +31.42% per trade.
2 Years
John NewmanCanaccord Genuity
Success Rate
10/12 ratings generated profit
83%
Average Return
+77.60%
Copying John Newman's trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +77.60% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

XE9 Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
7
8
7
7
6
Buy
3
7
10
14
10
Hold
3
3
1
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
18
18
24
19
In the current month, XE9 has received 16 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. XE9 average Analyst price target in the past 3 months is 28.23.
Each month's total comprises the sum of three months' worth of ratings.

XE9 Financial Forecast

XE9 Earnings Forecast

Next quarter’s earnings estimate for XE9 is -€0.34 with a range of -€1.08 to €0.20. The previous quarter’s EPS was -€0.26. XE9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year XE9 has Performed in-line its overall industry.
Next quarter’s earnings estimate for XE9 is -€0.34 with a range of -€1.08 to €0.20. The previous quarter’s EPS was -€0.26. XE9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year XE9 has Performed in-line its overall industry.

XE9 Sales Forecast

Next quarter’s sales forecast for XE9 is €52.56M with a range of €2.77M to €102.50M. The previous quarter’s sales results were €45.58M. XE9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year XE9 has Performed in-line its overall industry.
Next quarter’s sales forecast for XE9 is €52.56M with a range of €2.77M to €102.50M. The previous quarter’s sales results were €45.58M. XE9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year XE9 has Performed in-line its overall industry.

XE9 Stock Forecast FAQ

What is DE:XE9’s average 12-month price target, according to analysts?
Based on analyst ratings, Xencor Inc’s 12-month average price target is 28.23.
    What is DE:XE9’s upside potential, based on the analysts’ average price target?
    Xencor Inc has 28.32% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Xencor Inc a Buy, Sell or Hold?
          Xencor Inc has a consensus rating of Strong Buy, which is based on 11 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Xencor Inc’s share price target?
            The average share price target for Xencor Inc is 28.23. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €40.58 ,and the lowest forecast is €17.64. The average share price target represents 28.32% Increase from the current price of €22.
              What do analysts say about Xencor Inc?
              Xencor Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of Xencor Inc?
                To buy shares of DE:XE9, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.